BrightGene BioMedical

CompanyChina

BrightGene BioMedical develops one asset, in phase 3 (BGM0504 in type 2 diabetes). Mostly peptide acting on Insulin/IGF-1 signalling, lipid and ceramide metabolism and GLP1R; based in China.

1
Asset
Furthest stage: Phase 3; 0
Trials: 1
Signal

Pipeline

1

BGM0504
Activates GLP-1 and GIP receptors to improve glucose control and reduce body weight.
Phase 3, Peptide, Insulin/IGF-1 signalling, Lipid and ceramide metabolism, type 2 diabetes, obesity (Phase 2)

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms5
Signals5
Similar companies6

Papers

Safety, Pharmacokinetics, and Weight Loss Effects of the Oral GLP-1/GIP Dual Agonist BGM0504 in Healthy and Overweight or Obese Adults: A Phase 1 Multiple-Ascending Dose Study
ADA Scientific Sessions 2026 abstract, 6 Jun 2026